Table 1.
Patient baseline characteristics at the initiation of antiviral treatment
| Baseline characteristics | |
|---|---|
| Patient number | 474 |
| Age (years) | 58 (50–64) |
| Male, n (%) | 230 (48.5) |
| Body mass index (kg/m2) | 23.1 (21.0–25.3) |
| Alanine aminotransferase (U/L) | 52 (33–81) |
| Total cholesterol (mg/dL) | 174 (152–197) |
| α-fetoprotein (ng/mL) | 4.1 (2.5–7.2) |
| Platelet count (×109/L) | 160 (125–199) |
| Hemoglobin A1c (NGSP) (%) | 5.5 (5.3–5.9) |
| Fasting plasma glucose (mg/dL) | 93 (87–101) |
| Fasting serum insulin (μU/mL) | 8.6 (5.9–13.7) |
| HOMA-IR | 1.9 (1.3–3.3) |
| HCV RNA level (logIU/mL) | 6.2 (5.7–6.6) |
| HCV genotype, n (%) | |
| 1a | 4 (0.8) |
| 1b | 360 (75.9) |
| 2a | 63 (13.3) |
| 2b | 47 (9.9) |
| Fibrosis stage, n (%) | |
| F0-1 | 241 (50.8) |
| F2 | 104 (21.9) |
| F3 | 76 (16.0) |
| Not determined | 53 (11.2) |
| Activity grade, n (%) | |
| A0-1 | 162 (34.2) |
| A2 | 244 (51.5) |
| A3 | 15 (3.2) |
| Not determined | 53 (11.2) |
Data expressed as number (%) or median (first-third quartiles)
HOMA-IR, homeostasis model assessment of insulin resistance; HCV hepatitis C virus